✦ LIBER ✦

5075 Sunitinib plus docetaxel and trastuzumab as first-line therapy for HER2+ advanced breast cancer

✍ Scribed by F. Cardoso; J.L. Canon; D. Amadori; L. Dirix; E. Villa; D. Aldrighetti; J.P. Machiels; L. Verkh; K. Kern; C. Giorgetti

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An exploratory study of sunitinib in com

✍ Fatima Cardoso; Jean-Luc Canon; Dino Amadori; Daniela Aldrighetti; Jean-Pascal M 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 383 KB

Trastuzumab plus docetaxel with or witho

✍ A. Wardlev; A. Anton-Torres; X. Pivot; F. Morales-Vasquez; L. Zetina; M. de Fati 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 69 KB

Randomized phase III trial of trastuzuma

✍ Kenichi Inoue; Kazuhiko Nakagami; Mitsuhiro Mizutani; Yasuo Hozumi; Yasuhiro Fuj 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 368 KB

Everolimus plus exemestane as first-line

✍ Beck, J. Thaddeus; Hortobagyi, Gabriel N.; Campone, Mario; Lebrun, Fabienne; Del 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 341 KB

Trastuzumab with either docetaxel or vin

✍ Stefania Redana; Michela Donadio; Franco Nolè; Maria Elena Jacomuzzi; Alessandra 📂 Article 📅 2010 🏛 BioMed Central 🌐 English ⚖ 309 KB

672 Randomised phase II trial (M77001) o

✍ J.-M. Extra; F. Cognetti; S. Chan; D. Maraninchi; R. Snyder; a. Lluch; M. Tubian 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 174 KB